[go: up one dir, main page]

NO20021379L - Benzodiazepine derivatives, preparation and use thereof - Google Patents

Benzodiazepine derivatives, preparation and use thereof

Info

Publication number
NO20021379L
NO20021379L NO20021379A NO20021379A NO20021379L NO 20021379 L NO20021379 L NO 20021379L NO 20021379 A NO20021379 A NO 20021379A NO 20021379 A NO20021379 A NO 20021379A NO 20021379 L NO20021379 L NO 20021379L
Authority
NO
Norway
Prior art keywords
preparation
benzodiazepine derivatives
prodrugs
compounds
values
Prior art date
Application number
NO20021379A
Other languages
Norwegian (no)
Other versions
NO20021379D0 (en
Inventor
Wilfried Lubisch
Michael Kock
Thomas Hoeger
Roland Grandel
Reinhold Mueller
Sabine Schult
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20021379L publication Critical patent/NO20021379L/en
Publication of NO20021379D0 publication Critical patent/NO20021379D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)

Abstract

Oppfinnelsen angår forbindelser med formel I og deres tautomere former, mulige enantiomere og diastereomere former og prodrugs derav, fremstilling og anvendelse derav, hvor verdiene har betydningen angitt i beskrivelsen.The invention relates to compounds of formula I and their tautomeric forms, possible enantiomeric and diastereomeric forms and prodrugs thereof, their preparation and use, the values having the meaning given in the description.

NO20021379A 1999-09-28 2002-03-20 Benzodiazepine derivatives, preparation and use thereof NO20021379D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (en) 1999-09-28 1999-09-28 Benzodiazepine derivatives, their production and use
PCT/EP2000/009023 WO2001023386A2 (en) 1999-09-28 2000-09-15 Benzodiazepin derivatives, the production and use thereof

Publications (2)

Publication Number Publication Date
NO20021379L true NO20021379L (en) 2002-03-20
NO20021379D0 NO20021379D0 (en) 2002-03-20

Family

ID=7923476

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021379A NO20021379D0 (en) 1999-09-28 2002-03-20 Benzodiazepine derivatives, preparation and use thereof

Country Status (21)

Country Link
EP (1) EP1222191B1 (en)
JP (1) JP2003510324A (en)
KR (1) KR20020031602A (en)
CN (1) CN1376156A (en)
AR (1) AR025721A1 (en)
AT (1) ATE310003T1 (en)
AU (1) AU7656700A (en)
BG (1) BG106444A (en)
BR (1) BR0014326A (en)
CA (1) CA2384265A1 (en)
DE (2) DE19946289A1 (en)
ES (1) ES2251405T3 (en)
HK (1) HK1048994A1 (en)
HU (1) HUP0203225A3 (en)
IL (1) IL148419A0 (en)
NO (1) NO20021379D0 (en)
PL (1) PL354118A1 (en)
SK (1) SK3802002A3 (en)
TR (1) TR200200820T2 (en)
WO (1) WO2001023386A2 (en)
ZA (2) ZA200104196B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261963T1 (en) 1999-01-11 2004-04-15 Agouron Pharma TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
EP2036984B1 (en) 2002-07-26 2012-02-22 BASF Plant Science GmbH Reversion of the negative selective effect of negative marker proteins as selection procedure
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
CA2599405A1 (en) 2005-03-08 2006-09-14 Basf Plant Science Gmbh Expression enhancing intron sequences
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
US20120324603A1 (en) 2009-11-27 2012-12-20 BASF Plant Sceience Company GmbH Chimeric Endonucleases and Uses Thereof
JP5944320B2 (en) 2009-11-27 2016-07-05 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー Optimized endonuclease and its use
CA2781693C (en) 2009-11-27 2018-12-18 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2984771T3 (en) 2012-06-13 2024-10-31 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US20150218110A1 (en) * 2012-09-05 2015-08-06 Bayer Cropscience Ag Use of substituted benzodiazepinones and benzazepinones or the salts thereof as active substances against abiotic plant stress
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
JP6579549B2 (en) 2014-05-16 2019-09-25 塩野義製薬株式会社 Tricyclic heterocyclic derivatives having HIV replication inhibitory action
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE20171514A1 (en) 2015-02-20 2017-10-20 Incyte Corp BICYCLE HETEROCYCLES AS FGFR INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
CN111138458A (en) 2015-05-29 2020-05-12 盐野义制药株式会社 Nitrogen-containing tricyclic derivatives having HIV replication inhibiting effect
CN105153195B (en) * 2015-09-01 2017-09-26 汤文建 A kind of tricyclic pyrazole [1,5 d] [1,4] benzo oxygen azatropylidene ketone derivatives and preparation method thereof and purposes
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
CR20200591A (en) 2018-05-04 2021-03-31 Incyte Corp Salts of an fgfr inhibitor
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115835908A (en) 2019-10-14 2023-03-21 因赛特公司 Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505257A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Derivatives of FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL93136A (en) * 1989-02-23 1995-01-24 Janssen Pharmaceutica Nv Tetrahydroimidazo (1,4) benzodiazepin-2-thione derivatives, their preparation and pharmaceutical compositions containing them
DE69624115T2 (en) * 1995-08-02 2003-06-18 Newcastle University Ventures Ltd., Jesmond BENZIMIDAZOLE COMPOUNDS
ECSP003637A (en) * 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES

Also Published As

Publication number Publication date
HUP0203225A3 (en) 2003-05-28
IL148419A0 (en) 2002-09-12
BG106444A (en) 2002-09-30
WO2001023386A2 (en) 2001-04-05
EP1222191B1 (en) 2005-11-16
HUP0203225A2 (en) 2003-01-28
ATE310003T1 (en) 2005-12-15
WO2001023386A3 (en) 2002-05-10
JP2003510324A (en) 2003-03-18
KR20020031602A (en) 2002-05-02
CA2384265A1 (en) 2001-04-05
ZA200104196B (en) 2002-07-25
SK3802002A3 (en) 2003-03-04
AU7656700A (en) 2001-04-30
ES2251405T3 (en) 2006-05-01
PL354118A1 (en) 2003-12-29
TR200200820T2 (en) 2002-09-23
BR0014326A (en) 2002-05-28
NO20021379D0 (en) 2002-03-20
HK1048994A1 (en) 2003-04-25
DE19946289A1 (en) 2001-03-29
EP1222191A2 (en) 2002-07-17
CN1376156A (en) 2002-10-23
DE50011656D1 (en) 2005-12-22
ZA200201494B (en) 2003-12-31
AR025721A1 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
NO20021379L (en) Benzodiazepine derivatives, preparation and use thereof
BG105650A (en) Azepinoindole derivatives, the production and use thereof
NO20054404L (en) 5,7-Diaminopyrazolo [4,3-D] Pyrimidines Useful in the Treatment of Hypertension
BG105515A (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
NO20062950L (en) 5,7-diaminopyrazolo-43-Dlpyrimidines with PDE-5 inhibitory activity
NO20054905L (en) 2-acylamino-4-phenylthiazole derivatives, methods for their preparation and use of the same as in therapeutics
MXPA02005844A (en) Inhibitors of protein kinases.
ATE288431T1 (en) SUBSTITUTED BIZYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
GEP20094736B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
NO20005264D0 (en) Heterocyclic substituted amides, their preparation and use
MY135841A (en) Novel benzodioxoles
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
NO20062256L (en) Hydroxyalkyl-substituted pyrido-7-pyrimidin-7-ones
NO20073465L (en) Benzothiazole derivatives
TW200503710A (en) Novel compounds
ES2249309T3 (en) COMPOUNDS OF 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA AS INHIBITORS OF CSBP / P39 KINASA.
MXPA04006266A (en) Pyrimidotriazines as phosphatase inhibitors.
ATE345349T1 (en) PURINE DERIVATIVES
MXPA05012953A (en) 3-arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents.
DK1313740T3 (en) Prodrugs of imidazopyridine derivatives
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
DK1362045T3 (en) 2-Thio-substituted imidazole derivatives and their use in the pharmaceutical industry
DK1463731T3 (en) Dibenzodiazepine derivatives, their preparation and use
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application